Misonix, Inc. (MSON) |
| 26.54 0 (0%) 04-24 15:47 |
| Open: | 25.38 |
| High: | 26.555 |
| Low: | 25.08 |
| Volume: | 157,169 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | NASDAQ Global Market |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 31.02 |
| Resistance 1: | 26.56 |
| Pivot price: | 26.01 |
| Support 1: | 25.17 |
| Support 2: | 24.31 |
| 52w High: | 26.99 |
| 52w Low: | 11.14 |
Misonix, Inc., together with its subsidiaries, designs, develops, manufactures, and markets minimally invasive surgical ultrasonic medical devices in the United States and internationally. The company's products include BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting and sculpting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells. Its products are used in various clinical specialties, such as neurosurgery, orthopedic surgery, general surgery, plastic surgery, wound care, and maxillo-facial surgical applications. The company sells its products through sales representatives and distributors. Misonix, Inc. was founded in 1959 and is based in Farmingdale, New York.
| EPS | -0.840 |
| Book Value | 7.770 |
| PEG Ratio | 0.00 |
| Gross Profit | 3.020 |
| Profit Margin (%) | -19.55 |
| Operating Margin (%) | -12.48 |
| Return on Assets (ttm) | -2.9 |
| Return on Equity (ttm) | -10.3 |
Fri, 29 Oct 2021
Misonix merges with Bioventus - Jones Day
Fri, 30 Jul 2021
Bioventus buying Misonix for $518M - bioworld.com
Wed, 23 Dec 2020
Misonix to Present at the 39th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Thu, 19 Dec 2019
CryoLife and Misonix Enter Into Distribution Agreement for NeoPatch - PR Newswire
Tue, 07 Mar 2017
Misonix, Inc. Enters into Exclusive Chinese Distribution Agreement for BoneScalpel - PR Newswire
Mon, 19 Dec 2016
Stavros G. Vizirgianakis Appointed President and CEO of Misonix - BioSpace
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |